M42, an Abu Dhabi-based global health leader, has announced a major collaboration with Oracle Health to advance preventative medicine and personalized care across the UAE. The initiative will focus on creating unified, longitudinal patient records by integrating genomic data directly into the healthcare system.
Pioneering Pharmacogenomics at the Point of Care
At the core of the partnership is the integration of data from the Emirati Genome Programme directly into the Oracle Health Foundation electronic health record (EHR). This will enable pharmacogenomic recommendations at the point of care, allowing clinicians to make data-driven decisions based on a patient’s unique genetic makeup.
This advancement aims to optimize healthcare delivery by prioritizing prevention and healthy longevity. By understanding a patient’s genetic predispositions, physicians can prescribe the most effective medications from the outset.
Dimitris Moulavasilis, Group Chief Executive Officer at M42, commented on the vision, “This programme will empower clinicians and patients with actionable insights and enable providers to deliver proactive, personalised care, shaping a healthier future for communities across the UAE. Together with Oracle, we are paving the way for a future where healthcare is predictive, personalised, and accessible to all.”
A New Era of Preventative Medicine
The collaboration is set to enhance treatment efficacy, improve preventive care strategies, and reduce the waste associated with prescribing ineffective medications. By tailoring treatments to an individual’s genetic profile, the initiative aligns with the UAE’s broader vision of pioneering health innovation.
“Delivering pharmacogenomic insights at the point of care will help doctors provide more personalised care and prescribe medications that are tailored to a patient’s genetic makeup,” said Seema Verma, Executive Vice President and General Manager at Oracle Health and Life Sciences. “The work Oracle Health and M42 are undertaking will help promote the long-term health and well-being of UAE’s citizens and aligns with the UAE’s vision of pioneering health innovation and delivering exceptional, patient-centric care.”
Dr. Fahed Al Marzooqi, Chief Executive Officer of M42’s Integrated Health Solutions platform, added, “Being able to inform the physician at the point of prescribing regarding the level of genetic compatibility a patient has with a certain drug will increase the likelihood that the most effective medication is prescribed the first time, resulting in faster treatment and recovery.”
About M42
M42 is a global tech-enabled health powerhouse committed to reshaping the future of health. By disrupting the traditional healthcare model, M42 is pioneering a new era of preventative and personalized health with a focus on health-tech, genomics, and clinical research. Headquartered in Abu Dhabi, the company is dedicated to creating a more sustainable and patient-centric healthcare ecosystem.
Source: Zawya
